Management of Reflux Esophagitis (Erosive Esophagitis)
For patients with erosive esophagitis, initiate daily proton pump inhibitor (PPI) therapy and maintain continuous daily dosing long-term—do not use on-demand or less-than-daily dosing, as this leads to high recurrence rates of erosive disease. 1
Initial Treatment Approach
Start with standard-dose PPI once daily, taken 30-60 minutes before the first meal for 8 weeks 1, 2. This represents Grade A evidence (strongly recommended) for healing esophagitis and achieving symptom relief. PPIs are superior to H2-receptor antagonists, which are superior to placebo 1.
If Inadequate Response After 4-8 Weeks:
- First, verify medication compliance
- Then increase to twice-daily PPI dosing (though not FDA-approved, this is supported by expert consensus and pharmacodynamic principles) 1, 2
- Twice-daily dosing represents the upper limit of empirical therapy—patients not responding should be considered treatment failures requiring further evaluation 1
Maintenance Therapy Strategy
Critical distinction: The management of erosive esophagitis differs fundamentally from non-erosive reflux disease.
For Confirmed Erosive Esophagitis:
- Continue daily PPI indefinitely (Grade A recommendation) 1
- Titrate down to the lowest effective dose based on symptom control, but maintain daily dosing 1
- Do NOT use on-demand therapy—this is Grade D (recommend against) because recurrence rates of erosive disease are unacceptably high with intermittent dosing 1
- Patients not maintained on continuous acid suppression have high recurrence rates of erosive disease 1
Evidence Strength:
Multiple randomized controlled trials demonstrate that daily PPI dramatically decreases recurrence of erosive esophagitis. When patients with healed erosive esophagitis are randomized to continuous versus on-demand therapy, erosive disease recurrence rates are high with on-demand dosing 1.
Severity-Based Considerations
For severe erosive esophagitis (Los Angeles Grade C or D):
- Consider vonoprazan (potassium-competitive acid blocker) as initial therapy if available, as it shows greater efficacy in severe cases 3, 4
- These patients have approximately 6% likelihood of developing Barrett's esophagus with healing 1
Important Clinical Nuances
Quality of Life vs. Disease Progression: The primary risk of reducing or discontinuing PPI therapy is increased symptom burden—not necessarily disease progression. There are no high-quality data showing that continuous antisecretory therapy alters the natural history of reflux disease beyond reducing the already-low incidence of peptic stricture 1. However, the decision to maintain therapy is driven by quality of life impact, and most patients with erosive esophagitis will require chronic therapy 1.
Progression Risk: Patients with healed mucosa at index endoscopy have low 7-year progression rates: 1.9% for stricture, 0.0% for Barrett's metaplasia, 0.1% for adenocarcinoma 1. Routine endoscopic monitoring is Grade D (recommend against) as it does not diminish cancer risk 1.
Common Pitfalls to Avoid
Do not use on-demand PPI for erosive esophagitis—this strategy only works for non-erosive disease where symptom control is the sole objective 1
Do not discontinue therapy prematurely—the likelihood of long-term spontaneous remission is low, and most patients will require chronic therapy 1
Do not add nocturnal H2-receptor antagonists to twice-daily PPI—there is no evidence of improved efficacy with this combination 1
Do not perform routine surveillance endoscopy—endoscopically monitoring chronic GERD has not been shown to reduce cancer risk 1
Surgical Considerations
Antireflux surgery (laparoscopic fundoplication or magnetic sphincter augmentation) can be considered for:
- Patients responsive to but intolerant of PPI therapy (Grade A recommendation) 1
- Patients with persistent troublesome symptoms (especially regurgitation) despite PPI therapy (Grade B recommendation) 1
However, do NOT recommend surgery for:
- Patients well-controlled on medical therapy (Grade D—recommend against) 1
- As an antineoplastic measure in Barrett's esophagus (Grade D—recommend against) 1
Surgery and PPI therapy show equivalent efficacy in maintaining healed mucosa at 7 years, but PPI should be strongly recommended as initial therapy due to superior safety profile 1.
Long-term Safety
Available data show no worrisome safety signals with PPIs. The most convincing associations are with Clostridium difficile colitis and bacterial gastroenteritis, but the magnitude of risk is slight 1. There is insufficient evidence to mandate bone density studies, calcium supplementation, or H. pylori screening solely because of PPI use 1.